These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 31427174)

  • 1. Improving the estimation of the global burden of antimicrobial resistant infections.
    Limmathurotsakul D; Dunachie S; Fukuda K; Feasey NA; Okeke IN; Holmes AH; Moore CE; Dolecek C; van Doorn HR; Shetty N; Lopez AD; Peacock SJ;
    Lancet Infect Dis; 2019 Nov; 19(11):e392-e398. PubMed ID: 31427174
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Disease burden, associated mortality and economic impact of antimicrobial resistant infections in Australia.
    Wozniak TM; Dyda A; Merlo G; Hall L
    Lancet Reg Health West Pac; 2022 Oct; 27():100521. PubMed ID: 35832237
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Zero or More: Methodological Challenges of Counting and Estimating Deaths Related to Antibiotic-resistant Infections.
    Temkin E; Carmeli Y
    Clin Infect Dis; 2019 Nov; 69(11):2029-2034. PubMed ID: 31102400
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antimicrobial stewardship: can we add pharmacovigilance networks to the toolbox?
    Habarugira JMV; Figueras A
    Eur J Clin Pharmacol; 2021 May; 77(5):787-790. PubMed ID: 33196869
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tackling antibiotic resistance in India.
    Wattal C; Goel N
    Expert Rev Anti Infect Ther; 2014 Dec; 12(12):1427-40. PubMed ID: 25353717
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A one health framework to estimate the cost of antimicrobial resistance.
    Morel CM; Alm RA; Årdal C; Bandera A; Bruno GM; Carrara E; Colombo GL; de Kraker MEA; Essack S; Frost I; Gonzalez-Zorn B; Goossens H; Guardabassi L; Harbarth S; Jørgensen PS; Kanj SS; Kostyanev T; Laxminarayan R; Leonard F; Hara GL; Mendelson M; Mikulska M; Mutters NT; Outterson K; Baňo JR; Tacconelli E; Scudeller L;
    Antimicrob Resist Infect Control; 2020 Nov; 9(1):187. PubMed ID: 33243302
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Methodological quality of studies evaluating the burden of drug-resistant infections in humans due to the WHO Global Antimicrobial Resistance Surveillance System target bacteria.
    Pezzani MD; Tornimbene B; Pessoa-Silva C; de Kraker M; Rizzardo S; Salerno ND; Harbarth S; Tacconelli E
    Clin Microbiol Infect; 2021 Jan; 27(5):687-96. PubMed ID: 33450389
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Measuring and mapping the global burden of antimicrobial resistance.
    Hay SI; Rao PC; Dolecek C; Day NPJ; Stergachis A; Lopez AD; Murray CJL
    BMC Med; 2018 Jun; 16(1):78. PubMed ID: 29860943
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advances in pharmacovigilance initiatives surrounding antimicrobial resistance-Indian perspective.
    Bairy LK; Nayak V; A A; Kunder SK
    Expert Opin Drug Saf; 2016 Aug; 15(8):1055-62. PubMed ID: 27142491
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Road to comprehensive estimation of antimicrobial resistance (AMR) disease burden in Japan.
    Tsuzuki S; Matsunaga N; Ohmagari N
    Glob Health Med; 2020 Jun; 2(3):164-167. PubMed ID: 33330801
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Estimating the Economic and Clinical Value of Reducing Antimicrobial Resistance to Three Gram-negative Pathogens in Japan.
    Matsumoto T; Darlington O; Miller R; Gordon J; McEwan P; Ohashi T; Taie A; Yuasa A
    J Health Econ Outcomes Res; 2021; 8(2):64-75. PubMed ID: 34703834
    [No Abstract]   [Full Text] [Related]  

  • 12. Using the best available data to estimate the cost of antimicrobial resistance: a systematic review.
    Wozniak TM; Barnsbee L; Lee XJ; Pacella RE
    Antimicrob Resist Infect Control; 2019; 8():26. PubMed ID: 30733860
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Methods for estimating the burden of antimicrobial resistance: a systematic literature review protocol.
    Naylor NR; Silva S; Kulasabanathan K; Atun R; Zhu N; Knight GM; Robotham J
    Syst Rev; 2016 Nov; 5(1):187. PubMed ID: 27821153
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modelling the Future Clinical and Economic Burden of Antimicrobial Resistance: The Feasibility and Value of Models to Inform Policy.
    Hillock NT; Merlin TL; Turnidge J; Karnon J
    Appl Health Econ Health Policy; 2022 Jul; 20(4):479-486. PubMed ID: 35368230
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The antimicrobial resistance containment and surveillance approach--a public health tool.
    Simonsen GS; Tapsall JW; Allegranzi B; Talbot EA; Lazzari S
    Bull World Health Organ; 2004 Dec; 82(12):928-34. PubMed ID: 15654407
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Health and economic burden of antimicrobial-resistant infections in Australian hospitals: a population-based model.
    Wozniak TM; Bailey EJ; Graves N
    Infect Control Hosp Epidemiol; 2019 Mar; 40(3):320-327. PubMed ID: 30887942
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An assessment of antimicrobial resistant disease threats in Canada.
    Garner MJ; Carson C; Lingohr EJ; Fazil A; Edge VL; Trumble Waddell J
    PLoS One; 2015; 10(4):e0125155. PubMed ID: 25905797
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quantifying the primary and secondary effects of antimicrobial resistance on surgery patients: Methods and data sources for empirical estimation in England.
    Naylor NR; Evans S; Pouwels KB; Troughton R; Lamagni T; Muller-Pebody B; Knight GM; Atun R; Robotham JV
    Front Public Health; 2022; 10():803943. PubMed ID: 36033764
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antimicrobial resistance in New Zealand: the evidence and a call for action.
    Pullon HW; Gommans J; Thomas MG; Metcalf S; Grainger R; Wild H
    N Z Med J; 2016 Oct; 129(1444):103-110. PubMed ID: 27806034
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.